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Abstract: A one-pot, two-step method has been developed for the synthesis of ethyl 2-
[(Z)-2-(4-cyanophenyl)-2-hydroxyvinyl]-4-(4-methoxyphenyl)-6-methyl-1,4-dihydro- 
pyrimidine-5-carboxylate, including a sulfide contraction step utilizing solution and solid 
phase synthesis. 
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Nonplanar 3,4-dihydropyrimidin-2(1H)-one derivatives (DHPMs) are attractive molecules for drug 
research because of their known multifaceted pharmacological profiles. Introduction of DHPMs 
resulted in the discovery of new kinds of calcium channel modulators [1], hepatitis B virus replication 
inhibitors [2], mitotic kinesin inhibitors [3] and 1a-adrenergic receptor antagonists [4]. It seems to be 
reasonable that DHPMs are privileged structures for drug research and modifications around this motif 
are of considerable importance.  
Due to our continuous efforts in search of new methods for modifying privileged hetreocycles, we 
report herein the synthesis of ethyl 2-[(Z)-2-(4-cyanophenyl)-2-hydroxyvinyl]-4-(4-methoxyphenyl)-6-
methyl-1,4-dihydropyrimidine-5-carboxylate (3) from ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-
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1,2,3,4-tetrahydropyrimidine-5-carboxylate (1) in a one-pot, two-step synthesis (Scheme 1). The 
reaction sequence includes the S-alkylation of DHPM 1 by the -bromoketone 2. The resulting 
intermediate undergoes in the presence of triphenylphosphine an Eschenmoser sulfide contraction to 
yield the desired product 3 [5]. Separation of the arising triphenylphosphine sulfide from the reaction 
mixture can be done by column chromatography, but is not an easy task. To prevent this costly 
separation procedure, we chose the application of polymer-bound triphenylphosphine. The reaction 
selectivity and yields of both phosphine agents are comparable. The presented synthetic method is well 
suited for a diversity-oriented synthesis strategy, using differently substituted Biginelli compounds and 
various -bromoketones. 
Scheme 1. DHMP 1 alkylation/sulfide contraction sequence yielding product 3. 
 
 
The title compound 3 has been fully characterized by 1H- and 13C-NMR, IR, Raman and ESI-TOF 
MS analysis. It was observed that the 1H NMR spectra of 3 show a duplicate set of some signals 
(approximately 3:1 ratio) due to different conformers of 3 in solution. No tautomeric form of 3 was 
observed in the NMR experiments. The 1H NMR as well as the 13C NMR did not show appropriate 
signals for the expected aliphatic CH2 group of a keto tautomer.  
 
Experimental Procedure 
 
To a suspension of ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate 1 (110 mg, 0.36 mmol, 1 equiv) in acetone (2 mL), powdered K2CO3 (75 mg, 0.54 mmol, 
1.5 equiv) and 2-bromo-4`-cyanoacetophenone 2 (96 mg, 0.43 mmol, 1.2 equiv) were added 
subsequently. The reaction mixture was vigorously shaken at ambient temperature in a 4 mL capped 
glass vial, using an automatic shaker. A colour change of the solution from light yellow to dark brown 
took place. After shaking at ambient temperature under TLC monitoring (ethyl acatate/hexane 1:1, Rf: 
0.3), complete conversion of 1 into the S-alkylated intermediate was observed after 30 min. Polymer-
bound triphenylphosphine (0.54 mmol) (polystyrene, 2% DVB, 3 mmol/g, Fluka) was added in one 
portion, and the reaction temperature was raised to 80 oC. Shaking of the suspension was continued for 
additional 10 h to complete the sulfide contraction reaction. For work-up, the polymer was filtered off 
and washed with approx. 5 mL of ethyl acetate. The collected filtrates were concentrated under 
reduced pressure and subjected to flash chromatography (Silica-60, 0.06–0.20 mm, ethyl acetat/hexane 
20% vol./vol.) to obtain pure viscous yellow product as an approx. 3:1 inseparable mixture of isomers 
in 65% (97 mg) yield. 
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HR-MS (ESI-Q-TOF) calcd. for C24H24N3O4 [MH]+: 418.1761 found [MH]+: 418.1769. 
UV-Vis (CH3CN),  (nm): 374, 282, 244, 193. 
IR (KBr, cm-1): 2977 (C-H aromatic), 2227 (-C≡N), 1700 (C=O), 1630 (C=C), 1573, 1532, 1509, 
1476, 1368, 1328, 1244, 1203, 1172, 1092, 1058, 1031. 
Raman (powder, ATR, cm-1): 2229, 1649, 1605, 1502, 1382, 1300, 1222, 1177, 1111, 872, 763. 
1H NMR (300 MHz, CDCl3),  (ppm): 1.13, 1.12 (t, 3H, J = 6.0 Hz, -OCH2CH3), 2.41, 2.33 (s, 3H, 
CH3), 3.71, 3.68 (s, 3H, OCH3), 4.03, 4.05 (q, 2H, J = 6.0 Hz, -OCH2CH3), 5.22 (s, 1H, CH), 5.28 (s, 
1H, CH), 5.63, 5.38 (1H, D2O exchangeable, OH), 6.77, 6.74 (d, 2H, J = 9.0 Hz, ArH), 7.17, 7.13  
(d, 2H, J = 9.0 Hz, ArH), 7.58, 7.54 (d, 2H, J = 9.0 Hz, ArH), 7.76, 7.72 (d, 2H, J = 9.0 Hz, ArH), 
12.72, 11.41 (br, 1H, D2O exchangeable, N1-H). The second set of 1H NMR signals (observed for the 
minor isomeric form) is italicized. 
13C NMR (75 MHz, CDCl3),  (ppm): 14.2, 19.3, 52.8, 55.3, 60.3, 79.0, 103.7, 114.2, 118.6, 127.1, 
128.0, 132.1, 135.8, 143.2, 144.3, 155.0, 159.5, 165.3, 183.9. 
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